Literature DB >> 21808028

Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals.

Rasmus Rabøl1, Kitt Falk Petersen, Sylvie Dufour, Clare Flannery, Gerald I Shulman.   

Abstract

Skeletal muscle insulin resistance has been implicated in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and atherogenic dyslipidemia associated with the metabolic syndrome by altering the distribution pattern of postprandial energy storage. We conducted a study to examine this hypothesis by reversing muscle insulin resistance with a single bout of exercise and measuring hepatic de novo lipogenesis and hepatic triglyceride synthesis after a carbohydrate-rich meal. We studied 12 healthy, young, lean, insulin resistant individuals in an interventional, randomized cross-over trial. The response to the ingestion of a carbohydrate-rich meal was studied at rest and after one 45-min bout of exercise on an elliptical trainer. Hepatic de novo lipogenesis was assessed by using (2)H(2)O, and changes in glycogen and fat content in liver and muscle were measured by (13)C and (1)H magnetic resonance spectroscopy, respectively. Exercise resulted in a greater than threefold increase in postprandial net muscle glycogen synthesis (P < 0.001), reflecting improved muscle insulin responsiveness, and a ≈40% reduction (P < 0.05) in net hepatic triglyceride synthesis. These changes in whole body energy storage were accompanied by a ≈30% decrease in hepatic de novo lipogenesis (P < 0.01) and were independent of changes in fasting or postprandial plasma glucose and insulin concentrations. These data demonstrate that skeletal muscle insulin resistance is an early therapeutic target for the treatment and prevention of atherogenic dyslipidemia and NAFLD in young insulin resistant individuals who are prone to develop the metabolic syndrome and type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21808028      PMCID: PMC3158147          DOI: 10.1073/pnas.1110105108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

Review 2.  Skeletal muscle glucose uptake during exercise: how is it regulated?

Authors:  Adam J Rose; Erik A Richter
Journal:  Physiology (Bethesda)       Date:  2005-08

3.  The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome.

Authors:  Kitt Falk Petersen; Sylvie Dufour; David B Savage; Stefan Bilz; Gina Solomon; Shin Yonemitsu; Gary W Cline; Douglas Befroy; Laura Zemany; Barbara B Kahn; Xenophon Papademetris; Douglas L Rothman; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-18       Impact factor: 11.205

Review 4.  Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.

Authors:  Hannele Yki-Järvinen
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

5.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

6.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Authors:  Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

7.  A microfluorometric method for the determination of free fatty acids in plasma.

Authors:  J Miles; R Glasscock; J Aikens; J Gerich; M Haymond
Journal:  J Lipid Res       Date:  1983-01       Impact factor: 5.922

Review 8.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

Review 9.  Diabetic dyslipidemia.

Authors:  R A Kreisberg
Journal:  Am J Cardiol       Date:  1998-12-17       Impact factor: 2.778

10.  Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

Authors:  Varman T Samuel; Zhen-Xiang Liu; Xianqin Qu; Benjamin D Elder; Stefan Bilz; Douglas Befroy; Anthony J Romanelli; Gerald I Shulman
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

View more
  62 in total

Review 1.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

2.  Reply to Constantin-Teodosiu et al.: mice with genetic PDH activation are not protected from high-fat diet-induced muscle insulin resistance.

Authors:  Max C Petersen; Yasmeen Rahimi; Joao-Paulo G Camporez; Dominik Pesta; Rachel J Perry; Michael J Jurczak; Gary W Cline; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-23       Impact factor: 11.205

3.  Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids.

Authors:  Daniel F Vatner; Sachin K Majumdar; Naoki Kumashiro; Max C Petersen; Yasmeen Rahimi; Arijeet K Gattu; Mitchell Bears; João-Paulo G Camporez; Gary W Cline; Michael J Jurczak; Varman T Samuel; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-06       Impact factor: 11.205

Review 4.  Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.

Authors:  Piers R Blackett; Dharambir K Sanghera
Journal:  J Clin Lipidol       Date:  2012-04-22       Impact factor: 4.766

5.  β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors.

Authors:  Lee D Roberts; Pontus Boström; John F O'Sullivan; Robert T Schinzel; Gregory D Lewis; Andre Dejam; Youn-Kyoung Lee; Melinda J Palma; Sondra Calhoun; Anastasia Georgiadi; Ming-Huei Chen; Vasan S Ramachandran; Martin G Larson; Claude Bouchard; Tuomo Rankinen; Amanda L Souza; Clary B Clish; Thomas J Wang; Jennifer L Estall; Alexander A Soukas; Chad A Cowan; Bruce M Spiegelman; Robert E Gerszten
Journal:  Cell Metab       Date:  2014-01-07       Impact factor: 27.287

6.  Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes.

Authors:  Kelly A Bowden Davies; Victoria S Sprung; Juliette A Norman; Andrew Thompson; Katie L Mitchell; Jason C G Halford; Jo A Harrold; John P H Wilding; Graham J Kemp; Daniel J Cuthbertson
Journal:  Diabetologia       Date:  2018-04-18       Impact factor: 10.122

7.  Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.

Authors:  D Foer; M Zhu; R L Cardone; C Simpson; R Sullivan; S Nemiroff; G Lee; R G Kibbey; K F Petersen; K L Insogna
Journal:  Osteoporos Int       Date:  2017-03-10       Impact factor: 4.507

Review 8.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

9.  Liver and diabetes. A vicious circle.

Authors:  Paola Loria; Amedeo Lonardo; Frank Anania
Journal:  Hepatol Res       Date:  2013-01       Impact factor: 4.288

Review 10.  Tissue-specific insulin signaling in the regulation of metabolism and aging.

Authors:  Jingjing Zhang; Feng Liu
Journal:  IUBMB Life       Date:  2014-08-04       Impact factor: 3.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.